Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19745891 | 0.92 | NR1H2 (0.55) | NR1H2NR1H3 | |
| SCHEMBL21196617 | 0.89 | NR1H2 (0.51) | NR1H2NR1H3 | |
| SCHEMBL19745452 | 0.88 | NR1H2 (0.47) | NR1H2NR1H3 | |
| SCHEMBL21196535 | 0.83 | NR1H2 (0.51) | NR1H2NR1H3 | |
| SCHEMBL19747650 | 0.82 | NR1H2 (0.45) | NR1H2NR1H3 | |
| SCHEMBL21196724 | 0.82 | NR1H2 (0.52) | NR1H2NR1H3 | |
| SCHEMBL21214132 | 0.80 | NR1H2 (0.51) | NR1H2NR1H3 | |
| SCHEMBL19746159 | 0.80 | NR1H2 (0.55) | NR1H2NR1H3 | |
| SCHEMBL21196654 | 0.79 | NR1H2 (0.47) | NR1H2NR1H3 | |
| SCHEMBL17220658 | 0.77 | NR1H2 (0.72) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475277-B1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-10-20 | — | — | EP | disclosed |
| EP-3475277-B1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-10-20 | — | — | EP | disclosed |
| US-11130741-B2 | Anti-infective heterocyclic compounds and uses thereof | BIOIMICS AB (SE) | 2021-09-28 | — | — | US | disclosed |
| US-11130741-B2 | Anti-infective heterocyclic compounds and uses thereof | BIOIMICS AB (SE) | 2021-09-28 | — | — | US | disclosed |
| US-20190233384-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2019-08-01 | — | — | US | disclosed |
| US-20190233384-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2019-08-01 | — | — | US | disclosed |
| EP-3475277-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | Bioimics AB (SE) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017222466-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233384-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | ELANE, MPO, NISCH | NR1H2 1265/4885NR1H3 1339/4885 |
| US-11130741-B2 | Anti-infective heterocyclic compounds and uses thereof | ELANE, MPO, NISCH | NR1H2 1265/4885NR1H3 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.